Clinical relevance has been recently reported by Wallwork et al. who demonstrated clinical benefit and decrease of IL-8 levels particularly in a subgroup of CRS patients with low levels of IgE that had been treated with erythromycin [7]. This evidence concerns the gene CXCL8 and congenital rubella syndrome.